Fairvoy Private Wealth LLC Acquires New Holdings in Guardant Health, Inc. $GH

by · The Markets Daily

Fairvoy Private Wealth LLC acquired a new position in Guardant Health, Inc. (NASDAQ:GH – Free Report) during the 3rd quarter, Holdings Channel reports. The firm acquired 7,126 shares of the company’s stock, valued at approximately $1,271,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Jackson Square Capital LLC bought a new stake in Guardant Health during the third quarter valued at approximately $451,000. IFP Advisors Inc increased its holdings in Guardant Health by 15.7% during the third quarter. IFP Advisors Inc now owns 1,700 shares of the company’s stock valued at $303,000 after buying an additional 231 shares during the last quarter. Forum Financial Management LP bought a new position in Guardant Health in the third quarter worth approximately $259,000. TD Waterhouse Canada Inc. raised its position in Guardant Health by 624.7% in the third quarter. TD Waterhouse Canada Inc. now owns 42,009 shares of the company’s stock worth $7,352,000 after acquiring an additional 36,212 shares during the period. Finally, KOM Wealth Management Group LLC bought a new position in Guardant Health in the third quarter worth approximately $203,000. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Guardant Health Trading Down 0.5%

Guardant Health stock traded down $0.72 during midday trading on Monday, hitting $157.88. The stock had a trading volume of 1,869,720 shares, compared to its average volume of 2,211,743. The firm’s fifty day moving average is $167.94 and its two-hundred day moving average is $139.53. The company has a market capitalization of $21.19 billion, a PE ratio of -45.24 and a beta of 1.58. Guardant Health, Inc. has a 52-week low of $65.96 and a 52-week high of $191.05.

Guardant Health (NASDAQ:GH – Get Free Report) last released its earnings results on Thursday, July 30th. The company reported ($0.42) EPS for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.34. The firm had revenue of $334.98 million for the quarter, compared to the consensus estimate of $314.23 million. During the same quarter in the previous year, the business posted ($0.44) EPS. Guardant Health’s revenue was up 44.3% on a year-over-year basis. As a group, equities research analysts predict that Guardant Health, Inc. will post -3.02 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. Guggenheim lifted their price target on shares of Guardant Health from $190.00 to $200.00 and gave the stock a “buy” rating in a research note on Thursday, October 1st. Piper Sandler restated an “overweight” rating on shares of Guardant Health in a research note on Tuesday, September 15th. Citigroup raised their target price on Guardant Health from $150.00 to $215.00 and gave the stock a “buy” rating in a report on Wednesday, July 8th. Royal Bank Of Canada lifted their target price on Guardant Health from $185.00 to $200.00 and gave the company an “outperform” rating in a research report on Friday, July 31st. Finally, Evercore reiterated an “outperform” rating and set a $200.00 target price on shares of Guardant Health in a research report on Monday, July 6th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $190.00.

View Our Latest Research Report on Guardant Health

Insiders Place Their Bets

In other news, CTO Darya Chudova sold 7,738 shares of the stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $178.00, for a total value of $1,377,364.00. Following the completion of the sale, the chief technology officer directly owned 70,635 shares of the company’s stock, valued at $12,573,030. This represents a 9.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Chris Freeman sold 63,605 shares of the stock in a transaction on Monday, August 10th. The stock was sold at an average price of $169.58, for a total transaction of $10,786,135.90. Following the completion of the sale, the insider directly owned 65,374 shares of the company’s stock, valued at approximately $11,086,122.92. This trade represents a 49.31% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 178,940 shares of company stock valued at $30,070,911. Insiders own 5.60% of the company’s stock.

Guardant Health Profile

(Free Report)

Guardant Health, Inc (NASDAQ:GH) is a precision oncology company that develops blood-based tests and data solutions designed to help detect cancer, guide treatment decisions and monitor patients over time. Its technologies analyze circulating tumor DNA and other molecular information from blood samples, supporting more accessible and less invasive alternatives to some tissue-based testing approaches.

The company’s products include Guardant360, which helps identify genomic alterations in advanced cancers and may inform targeted treatment selection; Guardant360 Response, designed to assess a patient’s response to therapy; and Guardant Reveal, which is used to detect minimal residual disease and recurrence risk in certain cancers.

Featured Articles

Want to see what other hedge funds are holding GH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Guardant Health, Inc. (NASDAQ:GH – Free Report).